(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
The Delight of Perusing: Book Proposals for Each Class- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- 5 Wellbeing Applications Assist You With remaining Fit
- 4 injured in shooting at North Carolina tree lighting ceremony
- Island Travel Guide: Must-Visit Objections for 2024
- 6 Spending plan 3D Printers with the Best Worth
- View as Your Number one: These Low-Sugar Food varieties You Ought to Attempt
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
